

BPC-157 — DOUBLE SUBSTITUTION WITHIN THE C-TERMINAL PHARMACOPHORE: ASP-10 → L- HOMOARGININE (HARG) AND ASP-11 → L-HOMOARGININE (HARG), CONVERTING THE TANDEM ACIDIC DD MOTIF INTO A TANDEM BASIC (HARG-HARG) MOTIF WHILE PRESERVING BACKBONE LENGTH AND THE AGLV HYDROPHOBIC TAIL

generated 2026-05-05T03:59:07.577891+00:00

DISCARDED REGENERATIVE

DOUBLE SUBSTITUTION WITHIN THE C-TERMINAL PHARMACOPHORE: ASP-10 → L-HOMOARGININE (HARG) AND ASP-11 → L-HOMOARGININE (HARG), CONVERTING THE TANDEM ACIDIC DD MOTIF INTO A TANDEM BASIC (HARG-HARG) MOTIF WHILE PRESERVING BACKBONE LENGTH AND THE AGLV HYDROPHOBIC TAIL

VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2

AVERAGE CONFIDENCE	PTM / IPTM	VERDICT
63.1%	0.353 / 0.223	DISCARDED
TARGET	UNIPROT	BINDING PROBABILITY
Vascular endothelial growth factor receptor 2	P35968	—

TLDR

—

EXECUTIVE SUMMARY

—

DETAILED ANALYSIS

no research brief recorded.

RESEARCH BRIEF

no research brief recorded.

SEQUENCES

NATIVE

GEPPPGKPADDAGLV

MODIFIED

GEPPPGKPA-hArg-hArg-AGLV

CITATIONS

1. **PMID** — (2017) — — Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
2. **PMID** — (2025) — — Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
3. **PMID** — (2025) — — BPC-157 Binding to SH3 Domains and Activation of Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Production
4. **PMID** — (2025) — — BPC-157 Predicted to Bind SH3 Domains and Activate Src Family Kinases: In Silico Modeling and Fluorescent Fusion Protein Validation
5. **PMID** — (2018) — — BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.
6. **PMID** — (2021) — — Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
7. **PMID** — (2025) — — Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

8. **PMID** — (2019) — — Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
9. **PMID** — (2025) — — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
10. **PMID** — (2022) — — Pentadecapeptide BPC 157 and the central nervous system.
11. **PMID** — (2026) — — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
12. **PMID** — (2021) — — Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.